FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 687 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Will This Cancer Metastasize? Check Its “Stickiness” May 6, 2025 EMA Recommends Extension of Indications for Durvalumab July 27, 2020 ¿Tener paneles solares o vivir cerca de una granja solar puede... April 6, 2023 Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... August 17, 2020 Load more HOT NEWS Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... Nature’s Bounty: Revitalizing the Discovery of New Cancer Drugs from Natural... Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,...
